Search for content, post, videos

Neste Jacobs involved in Asia’s largest biopharma project

agreement

Technology, engineering and project management company Neste Jacobs has worked on an assignment to prepare conceptual and basic design for Asia’s largest human blood plasma fractionation plant project.

These phases of the project are now successfully completed to enable the implementation of the project by Sichuan Yuanda Shuyang Pharmaceutical Company.

Neste Jacobs has accumulated vast experience in human plasma fractionation over the last 40 years and the company has in-depth understanding of plasma technologies, production processes, operational aspects and cost levels required for a fully functional human plasma fractionation plant. This highly regulated biopharmaceutical sector sets high standards for the design and operation of the facility. Product safety, regulatory compliance, traceability and robust operability must be built-in during all design steps starting from conceptual and basicdesign now completed by Neste Jacobs.

“This project demonstrates that we are the world’s leading expert in this very demanding bioindustry field”, says Neste Jacobs CEO, Jarmo Suominen. “We have thorough understanding of various blood plasma technologies and a comprehensive network of partnerships in this field taking us way beyond our competition.”

The plant now goes to the implementation phase, being built in China. “During the conceptual and basic phases of this project we have greatly contributed to our customer quality and functionality of the plant.

Our approach integrates technology, concepts and process knowledge within the automated operations and constructability. This way our customers can be confident about the functionality of the as such complex plasma fractionation plant”, says Neste Jacobs Bioindustries Sales Director, Kari Kaskes. “We are without doubt a number one company in front line development of global bioindustries.”